Is CBD Legal in Brazil?

Last reviewed: August 6, 2026.

CBD is legal in Brazil only through medical channels regulated by ANVISA. In February 2026 ANVISA published a new regulatory package — RDC 1.012/2026 (research), RDC 1.013/2026 (licensed domestic cultivation of low-THC cannabis for medicinal and research purposes), RDC 1.014/2026 (non-profit patient associations), and RDC 1.015/2026 (manufacture, import, prescription, and pharmacy dispensing of Cannabis Products) — that replaces the framework created by RDC 327/2019, which RDC 1.015/2026 expressly revokes. The new rules entered into force in early August 2026. Authorized products must contain predominantly CBD; products with more than 0.2% THC remain restricted to patients with terminal, treatment-refractory, or serious debilitating conditions, and compounding pharmacies may now prepare cannabis derivatives. There is still no over-the-counter or wellness CBD market.

Patients who cannot access ANVISA-authorized products domestically may import CBD for personal use under RDC 660/2022, which remains in force and was deliberately kept outside the 2026 overhaul pending separate review. Patients or their legal representatives register through the gov.br portal, upload a valid medical prescription, and obtain an exceptional import authorization valid for up to two years. About 47% of Brazilian medical cannabis patients still rely on this personal-import route. Following a Superior Tribunal de Justiça ruling, RDC 1.013/2026 also authorizes licensed cultivation of hemp capped at 0.3% THC for pharmaceutical and research use. Habeas corpus rulings have also allowed select patients to cultivate at home for medicinal use. Mevatyl (nabiximols) remains the only fully registered cannabis-based medicine, approved in January 2017 for multiple sclerosis spasticity.

This page is for informational purposes only and does not constitute legal advice. Verify current law with qualified counsel before making compliance decisions.